Research programme: CAR-NK cell therapy - iCell Gene Therapeutics
Alternative Names: universal CAR-NK cell therapy - iCell Gene TherapeuticsLatest Information Update: 04 Dec 2023
At a glance
- Originator iCell Gene Therapeutics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 30 Nov 2023 Research programme: CAR-NK cell therapy - iCell Gene Therapeutics is available for licensing as of 30 Nov 2023. https://www.icellgene.com/collaborators
- 30 Nov 2023 Preclinical trials in Solid tumours in USA (Parenteral), prior to November 2023 (iCell Gene Therapeutics pipeline, November 2023)